Three new executives at Freenome

Freenome Inc. named three new executives as it prepares to commercialize its early cancer detection blood tests. Sally Howard joins as SVP, regulatory and quality, Charles Mwangi as CFO, and Julie Tran as chief people officer. Howard was VP of regulatory affairs and quality at Adaptive Biotechnologies Corp. (NASDAQ:ADPT) and deputy commissioner of policy, planning and legislation at FDA. Mwangi was SVP and CFO for the flash division of Western Digital Corp. (NASDAQ:WDC) and Tran was SVP of HR at Myovant Sciences GmbH (NYSE:MYOV). The cancer diagnostics company, which uses a multi-omics platform, has raised at least $1.1 billion to date.

Fibroblast cell company FibroBiologics hired Mark Andersen as CFO. Andersen was CFO and VP of administration at Indiana Biosciences Research Institute, before which he held financial roles at MiMedx Group Inc. (NASDAQ:MDXG) and Eli Lilly and Co. (NYSE:LLY)...